ABT vs BSX
ABT: A diversified global health care leader focused on diagnostic, medical device, nutritional, and pharmaceutical solutions. BSX: Boston Scientific is a leading medical device company dedicated to transforming lives through innovative, less-invasive medical solutions for a broad range of interventional specialties.
Side-by-side fundamentals
| Metric | ABT | BSX | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $116.67 | $49.01 | |
| Market cap as of 2026-08-25 | $203.2B | $71.0B | |
| P/E as of 2026-08-25 | 35.52 | 20.40 | BSX lower |
| PEG as of 2026-08-25 | 3.63 | 0.44 | BSX lower |
| Net margin as of 2026-08-25 | +11.7% | +17.5% | BSX higher |
| Gross margin as of 2026-08-25 | +56.8% | +69.5% | BSX higher |
| Operating margin as of 2026-08-25 | +15.8% | +19.8% | BSX higher |
| ROE as of 2026-08-25 | +10.5% | +14.9% | BSX higher |
| ROA as of 2026-08-25 | +5.6% | +8.3% | BSX higher |
| Debt / equity as of 2026-08-25 | 0.64 | 0.51 | BSX lower |
| Revenue growth (YoY) as of 2026-08-25 | +8.1% | +13.5% | BSX higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | +16.5% | BSX higher |
| Dividend yield as of 2026-08-25 | +2.0% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | n/a | |
| Beta as of 2026-08-25 | 0.58 | 0.57 | |
| 1-year return as of 2026-08-24 close | -12.0% | -53.8% | ABT higher |
Fundamentals: market data, as of 2026-08-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.